S&P 500   4,596.10 (+0.64%)
DOW   34,590.69 (+0.31%)
QQQ   394.15 (+0.08%)
AAPL   167.81 (+1.52%)
MSFT   335.49 (+1.48%)
FB   317.07 (-2.28%)
GOOGL   2,876.71 (+1.37%)
AMZN   3,496.16 (-0.31%)
TSLA   1,135.59 (-0.80%)
NVDA   322.08 (-1.43%)
BABA   125.01 (-1.98%)
NIO   39.47 (+0.87%)
CGC   10.27 (-4.11%)
AMD   152.78 (-3.53%)
GE   94.98 (-0.01%)
MU   87.06 (+3.64%)
T   22.49 (-1.49%)
F   19.96 (+4.01%)
DIS   144.31 (-0.41%)
PFE   54.36 (+1.17%)
ACB   6.18 (-3.74%)
AMC   31.26 (-7.90%)
BA   192.86 (-2.52%)
S&P 500   4,596.10 (+0.64%)
DOW   34,590.69 (+0.31%)
QQQ   394.15 (+0.08%)
AAPL   167.81 (+1.52%)
MSFT   335.49 (+1.48%)
FB   317.07 (-2.28%)
GOOGL   2,876.71 (+1.37%)
AMZN   3,496.16 (-0.31%)
TSLA   1,135.59 (-0.80%)
NVDA   322.08 (-1.43%)
BABA   125.01 (-1.98%)
NIO   39.47 (+0.87%)
CGC   10.27 (-4.11%)
AMD   152.78 (-3.53%)
GE   94.98 (-0.01%)
MU   87.06 (+3.64%)
T   22.49 (-1.49%)
F   19.96 (+4.01%)
DIS   144.31 (-0.41%)
PFE   54.36 (+1.17%)
ACB   6.18 (-3.74%)
AMC   31.26 (-7.90%)
BA   192.86 (-2.52%)
S&P 500   4,596.10 (+0.64%)
DOW   34,590.69 (+0.31%)
QQQ   394.15 (+0.08%)
AAPL   167.81 (+1.52%)
MSFT   335.49 (+1.48%)
FB   317.07 (-2.28%)
GOOGL   2,876.71 (+1.37%)
AMZN   3,496.16 (-0.31%)
TSLA   1,135.59 (-0.80%)
NVDA   322.08 (-1.43%)
BABA   125.01 (-1.98%)
NIO   39.47 (+0.87%)
CGC   10.27 (-4.11%)
AMD   152.78 (-3.53%)
GE   94.98 (-0.01%)
MU   87.06 (+3.64%)
T   22.49 (-1.49%)
F   19.96 (+4.01%)
DIS   144.31 (-0.41%)
PFE   54.36 (+1.17%)
ACB   6.18 (-3.74%)
AMC   31.26 (-7.90%)
BA   192.86 (-2.52%)
S&P 500   4,596.10 (+0.64%)
DOW   34,590.69 (+0.31%)
QQQ   394.15 (+0.08%)
AAPL   167.81 (+1.52%)
MSFT   335.49 (+1.48%)
FB   317.07 (-2.28%)
GOOGL   2,876.71 (+1.37%)
AMZN   3,496.16 (-0.31%)
TSLA   1,135.59 (-0.80%)
NVDA   322.08 (-1.43%)
BABA   125.01 (-1.98%)
NIO   39.47 (+0.87%)
CGC   10.27 (-4.11%)
AMD   152.78 (-3.53%)
GE   94.98 (-0.01%)
MU   87.06 (+3.64%)
T   22.49 (-1.49%)
F   19.96 (+4.01%)
DIS   144.31 (-0.41%)
PFE   54.36 (+1.17%)
ACB   6.18 (-3.74%)
AMC   31.26 (-7.90%)
BA   192.86 (-2.52%)
NYSE:ANVS

Annovis Bio Stock Forecast, Price & News

$22.49
-1.57 (-6.53%)
(As of 12/1/2021 01:51 PM ET)
Add
Compare
Today's Range
$22.49
▼
$23.99
50-Day Range
$24.06
▼
$37.67
52-Week Range
$5.25
▼
$132.00
Volume
794 shs
Average Volume
659,999 shs
Market Capitalization
$182.19 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.86
View Price History Chart DataSkip Price History Chart
30 days | 90 days | 365 days | Advanced Chart
Receive ANVS News and Ratings via Email

Sign-up to receive the latest news and ratings for Annovis Bio and its competitors with MarketBeat's FREE daily newsletter.


Annovis Bio logo

About Annovis Bio

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is ANVS401, which is in Phase 2a clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, Alzheimer's disease in Down Syndrome, and other chronic neurodegenerative disorders. It is also developing ANVS405 for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania.

Headlines

DEADLINE TODAY: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Annovis Bio, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
October 18, 2021 |  finance.yahoo.com
ANNOVIS DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Annovis Bio, Inc. and Encourages Investors to Contact ...
October 16, 2021 |  businesswire.com
FINAL NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Annovis Bio, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit – ANVS
October 14, 2021 |  feeds.benzinga.com
Deadline in 4 Days: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Class Action Lawsuit Against Annovis Bio, Inc. (ANVS)
October 14, 2021 |  finance.yahoo.com
ANVS Upcoming Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds Annovis Bio, Inc. Shareholders of Class Action and Lead Plaintiff Deadline: October 18, 2021
October 11, 2021 |  businesswire.com
INVESTOR ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Class Action Lawsuits filed on behalf of ANVS, HNST, PYPL Investors, Lead Plaintiff Deadlines Set
October 11, 2021 |  finance.yahoo.com
7-DAY DEADLINE ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Annovis Bio, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
October 11, 2021 |  finance.yahoo.com
Annovis Bio, Inc. Class Action Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Shareholders of Deadline in Securities Fraud Class Action Lawsuit
October 11, 2021 |  finance.yahoo.com
SHAREHOLDER ALERT: PHG KPLT ANVS: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
October 11, 2021 |  finance.yahoo.com
DEADLINE NEXT WEEK: Annovis Bio, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - ANVS
October 11, 2021 |  finance.yahoo.com
UPCOMING DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Annovis Bio, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit – ANVS
October 9, 2021 |  finance.yahoo.com
ANNOVIS BIO, INC. (ANVS) INVESTOR CLASS ACTION LAWSUIT DEADLINE: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Annovis Bio, Inc.
October 9, 2021 |  finance.yahoo.com
SLQT, ANVS & VIEW Class Action Reminders and Lead Plaintiff Deadlines - Bronstein, Gewirtz & Grossman, LLC
October 5, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Stock Exchange
NYSE
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NYSE:ANVS
Previous Symbol
CUSIP
N/A
CIK
1477845
Web
www.annovisbio.com
Phone
610-727-3913
Fax
N/A
Employees
2
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.09 per share
Price / Book
20.63

Profitability

EPS (Most Recent Fiscal Year)
($1.41)
Net Income
$-5.46 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-38.40%
Return on Assets
-36.96%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
42.51
Quick Ratio
42.51

Price-To-Earnings

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A

Miscellaneous

Outstanding Shares
8,101,000
Free Float
4,650,000
Market Cap
$182.19 million
Optionable
Not Optionable

Company Calendar

Last Earnings
11/02/2021
Today
12/01/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
3/02/2022

MarketRank™

Overall MarketRank™

2.37 out of 5 stars

Medical Sector

217th out of 1,392 stocks

Pharmaceutical Preparations Industry

88th out of 669 stocks

Analyst Opinion: 3.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 0.0 5 -4 -3 -2 -1 -












Annovis Bio (NYSE:ANVS) Frequently Asked Questions

Is Annovis Bio a buy right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Annovis Bio in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Annovis Bio stock.
View analyst ratings for Annovis Bio or view top-rated stocks.

When is Annovis Bio's next earnings date?

Annovis Bio is scheduled to release its next quarterly earnings announcement on Wednesday, March 2nd 2022.
View our earnings forecast for Annovis Bio.

How were Annovis Bio's earnings last quarter?

Annovis Bio, Inc. (NYSE:ANVS) released its quarterly earnings results on Tuesday, November, 2nd. The company reported ($0.35) EPS for the quarter, topping analysts' consensus estimates of ($0.44) by $0.09.
View Annovis Bio's earnings history.

What price target have analysts set for ANVS?

1 analysts have issued 12 month target prices for Annovis Bio's stock. Their forecasts range from $70.00 to $70.00. On average, they anticipate Annovis Bio's share price to reach $70.00 in the next twelve months. This suggests a possible upside of 211.2% from the stock's current price.
View analysts' price targets for Annovis Bio or view top-rated stocks among Wall Street analysts.

Who are Annovis Bio's key executives?

Annovis Bio's management team includes the following people:
  • Dr. Maria L. MacCecchini, Founder, CEO, Pres & Director (Age 70, Pay $420k)
  • Mr. Jeffrey B. McGroarty CPA, Chief Financial Officer (Age 52, Pay $300k)
  • Dr. Jeffrey L. Cummings, Chief Medical Advisor & Member of Scientific Advisory Board (Age 71)
  • Dr. William C. Mobley, Chief Scientific Advisor & Member of Scientific Advisory Board

What other stocks do shareholders of Annovis Bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Annovis Bio investors own include ADMA Biologics (ADMA), Bionano Genomics (BNGO), KushCo (KSHB), Matinas BioPharma (MTNB), Zosano Pharma (ZSAN), Auxly Cannabis Group (CBWTF), Novan (NOVN), Sorrento Therapeutics (SRNE), Cannabics Pharmaceuticals (CNBX) and Enerplus (ERF).

When did Annovis Bio IPO?

(ANVS) raised $10 million in an initial public offering on Wednesday, January 29th 2020. The company issued 1,400,000 shares at a price of $6.00-$8.00 per share. ThinkEquity (a division of Fordham Financial Management, Inc. ) served as the underwriter for the IPO.

What is Annovis Bio's stock symbol?

Annovis Bio trades on the New York Stock Exchange (NYSE) under the ticker symbol "ANVS."

Who are Annovis Bio's major shareholders?

Annovis Bio's stock is owned by a variety of retail and institutional investors. Top institutional investors include Voloridge Investment Management LLC (1.34%), BlackRock Inc. (1.28%), Two Sigma Investments LP (1.20%), AIGH Capital Management LLC (0.82%), Millennium Management LLC (0.81%) and Wescott Financial Advisory Group LLC (0.51%). Company insiders that own Annovis Bio stock include Claudine Bruck, Maria-Luisa Maccecchini and Reid Mccarthy.
View institutional ownership trends for Annovis Bio.

Which major investors are selling Annovis Bio stock?

ANVS stock was sold by a variety of institutional investors in the last quarter, including AIGH Capital Management LLC, Sterling Investment Advisors Ltd., and Modera Wealth Management LLC.
View insider buying and selling activity for Annovis Bio or view top insider-selling stocks.

Which major investors are buying Annovis Bio stock?

ANVS stock was purchased by a variety of institutional investors in the last quarter, including Two Sigma Investments LP, Millennium Management LLC, Wescott Financial Advisory Group LLC, Citadel Advisors LLC, Two Sigma Advisers LP, Essex LLC, Advisor Group Holdings Inc., and Morgan Stanley. Company insiders that have bought Annovis Bio stock in the last two years include Claudine Bruck, Maria-Luisa Maccecchini, and Reid Mccarthy.
View insider buying and selling activity for Annovis Bio or or view top insider-buying stocks.

How do I buy shares of Annovis Bio?

Shares of ANVS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Annovis Bio's stock price today?

One share of ANVS stock can currently be purchased for approximately $22.49.

How much money does Annovis Bio make?

Annovis Bio has a market capitalization of $182.19 million. The company earns $-5.46 million in net income (profit) each year or ($1.41) on an earnings per share basis.

How many employees does Annovis Bio have?

Annovis Bio employs 2 workers across the globe.

What is Annovis Bio's official website?

The official website for Annovis Bio is www.annovisbio.com.

Where are Annovis Bio's headquarters?

Annovis Bio is headquartered at 1055 Westlakes Drive Suite 300, Berwyn PA, 19312.

How can I contact Annovis Bio?

Annovis Bio's mailing address is 1055 Westlakes Drive Suite 300, Berwyn PA, 19312. The company can be reached via phone at 610-727-3913 or via email at [email protected].


This page was last updated on 12/1/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

Twitter Facebook StockTwits

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.